Login / Signup

Fueling the Pipeline via Innovations in Organic Synthesis.

Eric A VoightStephen N GreszlerPhilip R Kym
Published in: ACS medicinal chemistry letters (2021)
The paramount importance of synthetic organic chemistry in the pharmaceutical industry arises from the necessity to physically prepare all designed molecules to obtain key data to feed the design-synthesis-data cycle, with the medicinal chemist at the center of this cycle. Synthesis specialists accelerate the cycle of medicinal chemistry innovation by rapidly identifying and executing impactful synthetic methods and strategies to accomplish project goals, addressing the synthetic accessibility bottleneck that often plagues discovery efforts. At AbbVie, Discovery Synthesis Groups (DSGs) such as Centralized Organic Synthesis (COS) have been deployed as embedded members of medicinal chemistry teams, filling the gap between discovery and process chemistry. COS chemists provide synthetic tools, scaffolds, and lead compounds to fuel the pipeline. Examples of project contributions from neuroscience, cystic fibrosis, and virology illustrate the impact of the DSG approach. In the first ten years of innovative science in pursuit of excellence in synthesis, several advanced drug candidates, including ABBV-2222 (galicaftor) for cystic fibrosis and foslevodopa/foscarbidopa for Parkinson's disease, have emerged with key contributions from COS.
Keyphrases
  • cystic fibrosis
  • small molecule
  • pseudomonas aeruginosa
  • public health
  • quality improvement
  • big data
  • emergency department
  • drug discovery
  • lung function
  • water soluble
  • single cell
  • data analysis
  • deep learning